Testavec signs cooperation agreement with Genewerk GMBH one the world’s leading companies operating in the field of vector efficacy and safety in Gene Therapy.
Genewerk and Brunel University were partners in the $1million Plus Crackit programme funded by GSK and Novartis under the auspices of NC3RS with the prime aim of reducing the use of animals in testing.
Now Testavec has been spun out of Brunel to provide safety assays based upon the work done under the Crackit programme and Testavec will work with Genewerk to obtain the very best safety data for clients.
Commenting on the collaboration Professor Susan Jobling CEO of Testavec said “ It is wonderful to be working with Manfred , Annette and the Genewerk team – we have complimentary skills and science and by combining our expertise we hope to offer a vector safety analysis service second to none”